Compare Mesoblast Limited (MESO) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Roblox Corp — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Roblox Corp trades at $35.56 (market cap $25.87B). The key difference: Roblox Corp is far larger — about 11.7× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| MESO | RBLX | |
|---|---|---|
Market Cap | $2.21B | $25.87B |
Sector | Technology | Media |
52-Week High | $20.96 | $141.56 |
52-Week Low | $12.88 | $35.54 |
Enterprise Value | $2.21B | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
RBLX trades at $35.76, down 3.48% in the last session, with a bearish technical outlook from moving averages. The company reported revenue growth to $4.89 billion in 2025 but remains unprofitable, with a net loss of $1.07 billion. Analyst consensus is mixed, with a $45.67 price target, while recent news highlights multiple class-action lawsuits filed against the company.
The outlook is clouded by persistent losses and legal challenges, though revenue growth and strong operating cash flow of $1.80 billion offer some fundamental support. Risks include profitability challenges and litigation, but the stock may appeal to growth-oriented investors if execution improves and losses narrow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
